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Case Report
For years, neoadjuvant chemotherapy for locally advanced pancreatic cancer is being investigated and radical surgical resection with 
laparoscopic approach is getting up to speed. Pathological complete remission is known as a predictive marker for a good prognosis 
for various carcinomas. Although there are a few case reports about pathological complete remission, there has been no case report 
of pathological complete remission resulted from successful extensive resection by laparoscopic surgery after a neoadjuvant modified 
FOLFIRINOX chemotherapy. A 68-year-old male patient was admitted due to a palpable abdominal mass which turned out to be 
16-cm-sized huge locally advanced left-sided pancreatic cancer with possible stomach, left adrenal gland, left kidney, and colon inva-
sion. After administration of 10th modified FOLFIRINOX chemotherapy, the tumor had decreased and he underwent laparoscopic 
radical distal pancreatectomy with splenectomy, left adrenalectomy, wedge resection of stomach, and segmental resection of transverse 
colon. Although patient had a postoperative micro-abscess around the colon anastomosis site, he was successfully managed with con-
servative treatment and discharged on 12 days postoperatively. The final pathology reported complete tumor regression. We hereby 
emphasize the oncologic significance of neoadjuvant chemotherapy in huge left-sided pancreatic cancer and the potential role of lapa-
roscopic conversion surgery.
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INTRODUCTION
Pancreatic cancer is a cancer with a poor prognosis. Its 5-year 
survival rate is less than 5% [1]. Although surgical resection is 
the most effective treatment, only 15% to 20% of patients could 
be operated at the time of diagnosis because most patients are 
found to be in an advanced stage of the cancer [1]. Thus, neo-
adjuvant chemotherapy, which enables surgery for advanced 
pancreatic cancer that could not be operated at time of diag-
nosis, is gaining prominence in pancreatic cancer. For years, 
neoadjuvant chemotherapy for locally advanced pancreatic 
cancer is being investigated and radical surgical resection with 
laparoscopic method is getting up to speed.
Locally advanced pancreatic cancer is mostly associated with 
major vascular involvement [2]. In particular, when the superi-
or mesenteric artery or the celiac trunk is surrounded by a tu-
mor, or when the superior mesenteric vein/superior mesenteric 
vein-portal vein confluence is blocked, it can be defined as a 
locally advanced or un-resectable case [2]. For such cases, neo-
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adjuvant chemotherapy is recommended. FOLFIRINOX (fluo-
rouracil, oxaliplatin, leucovorin, irinotecan) regimen has been 
established itself as a standard treatment for locally advanced 
pancreatic cancer [3-5].
In the past, for a locally advanced pancreatic cancer, it was 
natural to proceed with open surgery because surgical access 
was difficult and extensive combined resection of surrounding 
organs, massive bleeding, and long operation time were ex-
pected. However, advances in laparoscopic technology have en-
abled us to see the potential of extensive laparoscopic resection 
for well selected locally advanced pancreatic cancer [6].
In various carcinomas, pathological complete remission 
is known as a predictive marker for a good prognosis [7]. 
Moreover, confirming a complete response of the tumor after 
neoadjuvant chemotherapy is expected to predict a patient’s 
long-term survival [7]. Much research is needed on whether 
complete remission means a good survival even for pancreatic 
cancer with a poor prognosis. Although few case reports have 
been reported [8,9], there has been no case reports of patholog-
ical complete remission due to successful extensive resection by 
laparoscopic surgery after a neoadjuvant modified FOLFIRI-
NOX chemotherapy.
We report a case of pathological complete remission of local-
ly advanced pancreatic cancer successfully managed by lapa-
roscopic radical resection following a neoadjuvant modified 
FOLFIRINOX chemotherapy. 
CASE
Case presentation
A 68-year-old male patient had visited our outpatient clinic 
due to a palpable abdominal mass presented from 3 months 
ago. The patient had diabetes mellitus, chronic obstructive 
pulmonary disease, and former prostate cancer treated with 
proton therapy 13 years ago. Initial radiological evaluations 
showed a 16-cm-sized large solid mass in the pancreas body 
and tail with splenic hilum lymph node enlargements, splenic 
vessel invasion, and possible tumor abutment to the stomach, 
the left adrenal gland, the left kidney, and the colon. No oth-
er major vessel involvement was noted (Fig. 1). Endoscopic 
ultrasonography-guided biopsy confirmed carcinoma with 
acinar pattern and extensive necrosis, consistent with acinar 
cell carcinoma. There was no distant metastasis found in chest 
computed tomography (CT) or positron emission tomography 
computed tomography (PET-CT). 
The first operation
A diagnostic laparoscopy was done on November 21st, 2019. 
Intraoperative findings were compatible with preoperative im-
age. It was observed that there was diffuse invasion of the tu-
mor to the mid-body of stomach with presumed adjacent organ 
invasions. The tumor even had extended to pancreatic head 
lesions, requiring total pancreatectomy for potential curative 
resection. Considering potential postoperative co-morbidity 
related to total pancreatectomy with combined multi-visceral 
resection, and aggressive tumor biology, an attempt for cu-
rative resection was aborted. Under the plan for neoadjuvant 
chemotherapy, the patient was discharged two days after post-
operative care. 
Neoadjuvant chemotherapy 
The first chemotherapy was started on January 23rd, 2020. 
Modified FOLFIRINOX [4] (oxaliplatin, 85 mg/m2; leucovorin, 
400 mg/m2; irinotecan, 150 mg/m2; and continuous fluoroura-
cil, 2,400 mg/m2; without bolus f luorouracil) with 20% dose 
reduction regimen was used at 2 week intervals. The patient 
well-tolerated the therapy. He did not suffer severe chemother-
apy-related complications other than mild nausea. After 10th 
doses, follow-up CT scan showed largely decreased tumor size 
from 16 cm to 10 cm without celiac or superior mesenteric ar-
tery invasion. No peritoneal seeding or distant metastasis was 
noted (Fig. 2). 
The second operation 
On July 10th, 2020, laparoscopic radical distal pancreatecto-
my was attempted. There was a large cystic tumor occupying 
pancreas tail, still abutting to the stomach posterior wall. Pan-
creas head lesion seemed to be preserved from the tumor. The 
pancreatic neck portion was safely dissected and divided. No 
definite tumor invasion around the celiac axis or the superior 
mesenteric artery was noted. Soft tissues around the celiac axis 
were dissected and both the splenic artery and the vein were 
Fig. 1. (A, B) Initial abdominopelvic com-
puted tomography showing a 16-cm sized 
mass in the pancreas body and tail abutting 
to stomach, left adrenal gland, left kidney, 
and colon with splenic vessel invasion.
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controlled. Stomach posterior wall was sleeved-resected with 
endoscopic gastrointestinal anastomosis stapler and re-en-
forced with knotless suture. Some parts of the splenic flexure 
of colon were invaded. Combined en bloc resection of colonic 
segment was performed. For tangential margin clearance, dis-
section of retroperitoneal soft tissues around the left kidney 
and left adrenalectomy were performed (Fig. 3). After bleeding 
control, two open silastic drains were inserted to be placed at 
the splenectomy site and the pancreatectomy site each. Total 
operation time was 437 minutes. Blood loss was 600 mL with-
out intraoperative transfusion. The patient was awoken and 
sent to the post-anesthesia care unit. Finally, he was sent to the 
general ward. 
Postoperative course and pathological examination 
Postoperative days (POD) were uneventful until POD #5 
when the open drain was removed and his fever spiked with 
mild leukocytosis observed. Abdominopelvic CT scan showed 
possible local peritonitis or ischemia of colon anastomosis with 
scarce f luid collection. However, conservative management 
with broad-spectrum intravenous antibiotics, transient nil per 
os, and nutritional support was sufficient. Finally, he was dis-
charged at 12 days postoperatively. The final pathologic report 
revealed complete regression of the tumor without residual 
carcinoma, showing cystic degeneration with necrosis (Fig. 4). 
He is now just followed up without chemotherapy. Up to date, 
there is no evidence of tumor recurrence.
Fig. 2. (A, B) Abdominopelvic computed 
tomography after administration of the 10th 
doses of modified FOLFIRINOX, showing 
decreased size and solidity of mass (arrow).
A B
104.78 mm
Fig. 3. (A) SpA (long white arrow) and SpV 
(short white arrows) were ligated and celiac 
artery dissection was done. (B) Left adrenal 
gland was resected and left pararenal fat 
layer were dissected. Note LRA and LRV, as 
well as resected spelnic artery (long white 
arrow). (C) Laparoscopic wedge resection 
o f  t h e  s to m a c h w a s  p e r f o r m e d w i t h 
endoscopic gastrointestinal anasomosis 
(GIA) stapler. (D) Segmental resection of 
the af fected colon was done with GIA 
stapler. CHA, common hepatic artery; LGA, 
left gastric artery; SpA, splenic artery; SpV, 
splenic vein; SMV, superior mesenteric vein; 
IMV, inferior mesenteric vein; Sp, spleen; P, 
pancreas; Ad, adrenal gland; LRA, left renal 
artery; LRV, left renal vein; K, kidney; G, 
stomach; C, colon.
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Fig. 4. Final pathology showed no residual carcinoma with cystic 
degeneration and necrosis.
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DISCUSSION
Preoperative chemotherapy for pancreatic cancer has become 
popular over the years. Neoadjuvant chemotherapy has its 
power in that it can increase the resectability by downsizing 
the tumor, increase R0 resection rate, cure micro-metastasis, 
and pre-select patients with good response to chemotherapy. 
Many randomized clinical trial and meta-analysis have 
shown the superiority of a neoadjuvant therapy in borderline 
resectable pancreas cancer [10,11]. Several randomized clinical 
trials are undergoing using modified FOLFIRINOX. Several 
retrospective studies have already shown that preoperative 
modified FOLFIRINOX can lead to improved resectability, 
downstaged tumor, and increased disease-free survival and 
overall survival [3-5]. 
Conversion surgery in unresectable pancreatic cancer after 
treatment with chemotherapy has empowered itself from many 
cases [5,12]. Neoadjuvant chemotherapy including modified 
FOLFIRINOX can improve the resectability and R0 resection 
rate of locally advanced pancreatic cancer [5,13]. 
Meanwhile, laparoscopic distal pancreatectomy for left sided 
pancreas cancer is known to have results comparable (or even 
feasible) to a conventional open distal pancreatectomy. Laparo-
scopic approach can result in less intraoperative blood loss, in-
traoperative transfusion, time to first flatus, time to start diet, 
length of hospital stay and perioperative complications [14,15]. 
Although controversy still exists, laparoscopic treatment could 
be endorsed within effective treatment modality for a left sided 
pancreatic cancer [16]. 
Laparoscopic surgery is often performed for an advanced left 
side pancreatic cancer. So far, there has been no report about 
a randomized control trial-determine whether a laparoscopic 
surgery has oncological significance in advanced left side pan-
creatic cancer. However, with the widespread use of FOLFIRI-
NOX, laparoscopic surgery is expected to increase in patients 
with a complete response after neoadjuvant FOLFIRINOX as a 
locally advanced pancreatic cancer in clinical practice. There-
fore, careful experience and research on these patients are 
needed.
Our institution has been performing laparoscopic radical 
distal pancreatectomy for left sided pancreas cancer for years 
for well-selected patients. Outcomes of a laparoscopic radical 
distal pancreatectomy were no inferior to those of an open sur-
gery [17,18]. Moreover, nowadays locally advanced pancreatic 
cancer can be properly managed with neoadjuvant therapy and 
subsequent operation in well-selected patients [8].
There are not so many case reports that illustrate locally ad-
vanced pancreatic cancer that totally resolves after a preoper-
ative chemotherapy. Luu et al. [9] have demonstrated a patient 
with pancreatic head cancer involving portal vein that has been 
treated with five cycles of FOLFIRINOX. The final pathologic 
report was complete resolution. However the pathologic com-
plete response did not designate an absolute cure. Some say 
they recur in up to 40%, which urges us to follow up patients 
more carefully and perform serial adjuvant chemotherapy as 
much as possible [19]. Also, pancreatic acinar cell carcinoma is 
a subtype that is rarely known for its chemoresponsiveness and 
surgical outcomes [20]. We should bear in mind that pancre-
atic acinar cell carcinoma does not represent most pancreatic 
cancer, which is a limitation when generalizing results of this 
study. 
We hereby report a case of pathological complete remission 
of locally advanced pancreatic cancer successfully managed by 
a laparoscopic radical distal pancreatectosplenectomy with a 
combined gastric wedge resection and a segmental resection 
of the colon after he was administrated with the neoadjuvant 
modified FOLFIRINOX chemotherapy. Most pancreatic cancer 
patients might be disappointed because they are initially found 
in an advanced state with cure seeming difficult. However, po-
tent neoadjuvant chemotherapy and subsequent safe curative 
pancreatectomy based on the patient’s eagerness for cure can 
brighten the future of pancreatic cancer.
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